BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lutz AM, Willmann JK, Goepfert K, Marincek B, Weishaupt D. Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging. Radiology. 2005;237:520-528. [PMID: 16192317 DOI: 10.1148/radiol.2372041183] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Stephen RM, Gillies RJ. Promise and Progress for Functional and Molecular Imaging of Response to Targeted Therapies. Pharm Res 2007;24:1172-85. [DOI: 10.1007/s11095-007-9250-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
2 Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB. Cirrhosis-associated Hepatocellular Nodules: Correlation of Histopathologic and MR Imaging Features. RadioGraphics 2008;28:747-69. [DOI: 10.1148/rg.283055108] [Cited by in Crossref: 130] [Cited by in F6Publishing: 93] [Article Influence: 9.3] [Reference Citation Analysis]
3 An C, Park MS, Kim D, Kim YE, Chung WS, Rhee H, Kim MJ, Kim KW. Added value of subtraction imaging in detecting arterial enhancement in small (<3 cm) hepatic nodules on dynamic contrast-enhanced MRI in patients at high risk of hepatocellular carcinoma. Eur Radiol 2013;23:924-30. [PMID: 23138382 DOI: 10.1007/s00330-012-2685-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
4 Fischer MA, Donati OF, Reiner CS, Hunziker R, Nanz D, Boss A. Feasibility of semiquantitative liver perfusion assessment by ferucarbotran bolus injection in double-contrast hepatic MRI. J Magn Reson Imaging 2012;36:168-76. [PMID: 22334302 DOI: 10.1002/jmri.23611] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
5 Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK, Goldstein RM. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent). 2008;21:266-280. [PMID: 18628926 DOI: 10.1080/08998280.2008.11928410] [Cited by in Crossref: 105] [Cited by in F6Publishing: 102] [Article Influence: 9.5] [Reference Citation Analysis]
6 Korkusuz H, Knau LL, Kromen W, Bihrer V, Keese D, Piiper A, Vogl TJ. Different signal intensity at Gd-EOB-DTPA compared with Gd-DTPA-enhanced MRI in hepatocellular carcinoma transgenic mouse model in delayed phase hepatobiliary imaging. J Magn Reson Imaging 2012;35:1397-402. [PMID: 22267126 DOI: 10.1002/jmri.23584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
7 Heilmaier C, Sutter R, Lutz AM, Seifert B, Weishaupt D, Marincek B, Willmann JK. Mapping of Hepatic Vascular Anatomy: Dynamic Contrast-enhanced Parallel MR Imaging Compared with 64–Detector Row CT. Radiology 2007;245:872-80. [DOI: 10.1148/radiol.2453062103] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
8 Golfieri R, Marini E, Bazzocchi A, Fusco F, Trevisani F, Sama C, Mazzella G, Cavuto S, Piscaglia F, Bolondi L. Small (<or=3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT. Radiol Med. 2009;114:1239-1266. [PMID: 19697104 DOI: 10.1007/s11547-009-0439-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
9 Saha S, Yang XB, Tanner S, Curran S, Wood D, Kirkham J. The effects of iron oxide incorporation on the chondrogenic potential of three human cell types. J Tissue Eng Regen M. 2013;7:461-469. [PMID: 22396122 DOI: 10.1002/term.544] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
10 Schäfer R, Ayturan M, Bantleon R, Kehlbach R, Pintaske J, Conrad S, Wolburg H, Wiskirchen J, Weissert R. The Use of Clinically Approved Small Particles of Iron Oxide (SPIO) for Labeling of Mesenchymal Stem Cells Aggravates Clinical Symptoms in Experimental Autoimmune Encephalomyelitis and Influences Their In Vivo Distribution. Cell Transplant 2008;17:923-41. [DOI: 10.3727/096368908786576480] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
11 Khatri G, Merrick L, Miller FH. MR imaging of hepatocellular carcinoma. Magn Reson Imaging Clin N Am. 2010;18:421-450, x. [PMID: 21094448 DOI: 10.1016/j.mric.2010.08.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
12 Daldrup-Link HE, Theruvath AJ, Rashidi A, Iv M, Majzner RG, Spunt SL, Goodman S, Moseley M. How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol. Pediatr Radiol 2021. [PMID: 34046709 DOI: 10.1007/s00247-021-05098-5] [Reference Citation Analysis]
13 Chen J, Si Y, Zhao K, Shi X, Bi W, Liu SE, Hua H. Evaluation of quantitative parameters of dynamic contrast-enhanced magnetic resonance imaging in qualitative diagnosis of hepatic masses. BMC Med Imaging 2018;18:56. [PMID: 30587152 DOI: 10.1186/s12880-018-0299-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Daniele Marin, Iannaccone R, Laghi A, Catalano C, Murakami T, Hori M, Kim T, Passariello R. Focal nodular hyperplasia: Intraindividual comparison of dynamic gadobenate dimeglumine- and ferucarbotran-enhanced magnetic resonance imaging. J Magn Reson Imaging 2007;25:775-82. [DOI: 10.1002/jmri.20885] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
15 Cereser L, Furlan A, Bagatto D, Girometti R, Como G, Avellini C, Orsaria M, Zuiani C, Bazzocchi M. Comparison of portal venous and delayed phases of gadolinium-enhanced magnetic resonance imaging study of cirrhotic liver for the detection of contrast washout of hypervascular hepatocellular carcinoma. J Comput Assist Tomogr 2010;34:706-11. [PMID: 20861773 DOI: 10.1097/RCT.0b013e3181e1a88e] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
16 Grazioli L, Bondioni MP, Romanini L, Frittoli B, Gambarini S, Donato F, Santoro L, Colagrande S. Superparamagnetic iron oxide-enhanced liver MRI with SHU 555 A (RESOVIST®): New protocol infusion to improve arterial phase evaluation-A prospective study. J Magn Reson Imaging 2009;29:607-16. [DOI: 10.1002/jmri.21644] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
17 Bargellini I, Battaglia V, Bozzi E, Lauretti DL, Lorenzoni G, Bartolozzi C. Radiological diagnosis of hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:137-48. [PMID: 27508183 DOI: 10.2147/JHC.S44379] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Low RN. Abdominal MRI advances in the detection of liver tumours and characterisation. Lancet Oncol. 2007;8:525-535. [PMID: 17540304 DOI: 10.1016/S1470-2045(07)70170-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
19 Kaufels N, Korn R, Wagner S, Schink T, Hamm B, Taupitz M, Schnorr J. Magnetic Resonance Imaging of Liver Metastases: Experimental Comparison of Anionic and Conventional Superparamagnetic Iron Oxide Particles With a Hepatobiliary Contrast Medium During Dynamic and Uptake Phases: . Investigative Radiology 2008;43:496-503. [DOI: 10.1097/rli.0b013e31816f1be1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
20 Marin D, Brancatelli G, Federle MP, Lagalla R, Catalano C, Passariello R, Midiri M, Vilgrain V. Focal nodular hyperplasia: typical and atypical MRI findings with emphasis on the use of contrast media. Clin Radiol. 2008;63:577-585. [PMID: 18374723 DOI: 10.1016/j.crad.2007.06.011] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
21 Kierans AS, Leonardou P, Hayashi P, Brubaker LM, Elazzazi M, Shaikh F, Semelka RC. MRI findings of rapidly progressive hepatocellular carcinoma. Magn Reson Imaging. 2010;28:790-796. [PMID: 20427139 DOI: 10.1016/j.mri.2010.03.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
22 Chen R, Lii J, Chou C, Chang T, Chen W, Li C, Tu H. T2-weighted and T1-weighted Dynamic Superparamagnetic Iron Oxide (Ferucarbotran) Enhanced MRI of Hepatocellular Carcinoma and Hyperplastic Nodules. Journal of the Formosan Medical Association 2008;107:798-805. [DOI: 10.1016/s0929-6646(08)60193-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
23 Park Y, Choi D, Kim SH, Kim SH, Kim MJ, Lee J, Lim JH, Lee WJ, Lim HK. Changes in signal-to-noise ratios and contrast-to-noise ratios of hypervascular hepatocellular carcinomas on ferucarbotran-enhanced dynamic MR imaging. European Journal of Radiology 2006;59:424-31. [DOI: 10.1016/j.ejrad.2006.06.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
24 Schäfer R, Kehlbach R, Müller M, Bantleon R, Kluba T, Ayturan M, Siegel G, Wolburg H, Northoff H, Dietz K, Claussen CD, Wiskirchen J. Labeling of human mesenchymal stromal cells with superparamagnetic iron oxide leads to a decrease in migration capacity and colony formation ability. Cytotherapy 2009;11:68-78. [DOI: 10.1080/14653240802666043] [Cited by in Crossref: 60] [Cited by in F6Publishing: 66] [Article Influence: 4.6] [Reference Citation Analysis]
25 Shimizu A, Ito K, Sasaki K, Hayashida M, Tanabe M, Shimizu K, Matsunaga N. Small hyperintense hepatic lesions on T1-weighted images in patients with cirrhosis: evaluation with serial MRI and imaging features for clinical benignity. Magn Reson Imaging. 2007;25:1430-1436. [PMID: 17524587 DOI: 10.1016/j.mri.2007.03.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
26 Schäfer R, Kehlbach R, Wiskirchen J, Bantleon R, Pintaske J, Brehm BR, Gerber A, Wolburg H, Claussen CD, Northoff H. Transferrin Receptor Upregulation: In Vitro Labeling of Rat Mesenchymal Stem Cells with Superparamagnetic Iron Oxide. Radiology 2007;244:514-23. [DOI: 10.1148/radiol.2442060599] [Cited by in Crossref: 77] [Cited by in F6Publishing: 75] [Article Influence: 5.1] [Reference Citation Analysis]
27 Martin DR, Lauenstein T, Kalb B, Lurie C, Kitajima H, Sharma P, Salman K, Moreira R, Farris AB 3rd, Spivey J, Martinez E, Hanish S, Adsay V. Liver MRI and histological correlates in chronic liver disease on multiphase gadolinium-enhanced 3D gradient echo imaging. J Magn Reson Imaging 2012;36:422-9. [PMID: 22566123 DOI: 10.1002/jmri.23668] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
28 Guiu B, Loffroy R, Ben Salem D, Lepage C, Guiu S, Aho S, Jouve JL, Krausé D, Cercueil JP. Combined SPIO-gadolinium magnetic resonance imaging in cirrhotic patients: negative predictive value and role in screening for hepatocellular carcinoma. Abdom Imaging 2008;33:520-8. [PMID: 17912584 DOI: 10.1007/s00261-007-9327-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
29 Sandrasegaran K, Tahir B, Patel A, Ramaswamy R, Bertrand K, Akisik FM, Saxena R. The usefulness of diffusion-weighted imaging in the characterization of liver lesions in patients with cirrhosis. Clin Radiol. 2013;68:708-715. [PMID: 23510619 DOI: 10.1016/j.crad.2012.10.023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
30 Korean Society of Abdominal Radiology. Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology. Korean J Radiol 2017;18:427-43. [PMID: 28458595 DOI: 10.3348/kjr.2017.18.3.427] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
31 Heilmaier C, Lutz AM, Bolog N, Weishaupt D, Seifert B, Willmann JK. Focal liver lesions: detection and characterization at double-contrast liver MR Imaging with ferucarbotran and gadobutrol versus single-contrast liver MR imaging. Radiology 2009;253:724-33. [PMID: 19789232 DOI: 10.1148/radiol.2533090161] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
32 Yoo HJ, Lee JM, Lee MW, Kim SJ, Lee JY, Han JK, Choi BI. Hepatocellular Carcinoma in Cirrhotic Liver: Double-Contrast-Enhanced, High-Resolution 3.0T-MR Imaging With Pathologic Correlation: . Investigative Radiology 2008;43:538-46. [DOI: 10.1097/rli.0b013e3181768d96] [Cited by in Crossref: 34] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
33 Tahir B, Sandrasegaran K, Ramaswamy R, Bertrand K, Mhapsekar R, Akisik FM, Saxena R. Does the hepatocellular phase of gadobenate dimeglumine help to differentiate hepatocellular carcinoma in cirrhotic patients according to histological grade? Clin Radiol 2011;66:845-52. [PMID: 21771548 DOI: 10.1016/j.crad.2011.03.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
34 Shinmura R, Matsui O, Kadoya M, Kobayashi S, Terayama N, Sanada J, Demachi H, Gabata T. Detection of hypervascular malignant foci in borderline lesions of hepatocellular carcinoma: comparison of dynamic multi-detector row CT, dynamic MR imaging and superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol 2008;18:1918-24. [PMID: 18386012 DOI: 10.1007/s00330-008-0954-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
35 Choi SY, Kim SH, Park CK, Min JH, Lee JE, Choi YH, Lee BR. Imaging Features of Gadoxetic Acid-enhanced and Diffusion-weighted MR Imaging for Identifying Cytokeratin 19-positive Hepatocellular Carcinoma: A Retrospective Observational Study. Radiology 2018;286:897-908. [PMID: 29166246 DOI: 10.1148/radiol.2017162846] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
36 Leoni S, Piscaglia F, Golfieri R, Camaggi V, Vidili G, Pini P, Bolondi L. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol. 2010;105:599-609. [PMID: 19935786 DOI: 10.1038/ajg.2009.654] [Cited by in Crossref: 136] [Cited by in F6Publishing: 126] [Article Influence: 10.5] [Reference Citation Analysis]
37 Kim YK, Kim CS, Han YM. Detection of small hepatocellular carcinoma: comparison of conventional gadolinium-enhanced MRI with gadolinium-enhanced MRI after the administration of ferucarbotran. Br J Radiol. 2009;82:468-484. [PMID: 19124563 DOI: 10.1259/bjr/76535286] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
38 Schäfer R, Bantleon R, Kehlbach R, Siegel G, Wiskirchen J, Wolburg H, Kluba T, Eibofner F, Northoff H, Claussen CD, Schlemmer HP. Functional investigations on human mesenchymal stem cells exposed to magnetic fields and labeled with clinically approved iron nanoparticles. BMC Cell Biol 2010;11:22. [PMID: 20370915 DOI: 10.1186/1471-2121-11-22] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 4.8] [Reference Citation Analysis]
39 Kim YK, Lee YH, Kwak HS, Kim CS, Han YM. Detection of liver metastases: Gadoxetic acid-enhanced three-dimensional MR imaging versus ferucarbotran-enhanced MR imaging. Eur J Radiol. 2010;73:131-136. [PMID: 18996659 DOI: 10.1016/j.ejrad.2008.09.027] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
40 Yang C, Xu K, Zheng J, Ma P, Hu C, Li S, Rong Y, Lu X, Zhang Q, Zu M, Hua R, Zhang L. Hepatocellular carcinoma in Budd-Chiari syndrome: enhancement patterns at dynamic gadolinium-enhanced T1-weighted MR imaging. Cell Biochem Biophys 2014;70:661-6. [PMID: 24760630 DOI: 10.1007/s12013-014-9970-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
41 Caraiani CN, Dan M, Fenesan DI, Badea R. Description of focal liver lesions with Gd-EOB-DTPA enhanced MRI. Clujul Med 2015;88:438-48. [PMID: 26733231 DOI: 10.15386/cjmed-414] [Reference Citation Analysis]
42 Hanna RF, Kased N, Kwan SW, Gamst AC, Santosa AC, Hassanein T, Sirlin CB. Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. AJR Am J Roentgenol. 2008;190:47-57. [PMID: 18094293 DOI: 10.2214/ajr.07.2595] [Cited by in Crossref: 39] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
43 Hong HS, Byun JH, Won HJ, Kim KW, Lee SS, Lee MG, Yun SC. Characterization of liver metastases: the efficacy of biphasic magnetic resonance imaging with ferucarbotran-enhancement. Clin Radiol 2010;65:701-7. [PMID: 20696297 DOI: 10.1016/j.crad.2010.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
44 Tsang LL, Chen CL, Huang TL, Chen TY, Ou HY, Eng HL, Concejero A, Yu CY, Chen HL, Cheng YF. Superparamagnectic iron oxide-enhanced magnetic resonance for tumor surveillance in cirrhotic liver before liver transplantation with explanted liver correlation. Transplant Proc 2011;43:1674-7. [PMID: 21693256 DOI: 10.1016/j.transproceed.2011.01.162] [Reference Citation Analysis]
45 Cheng WZ, Zeng MS, Yan FH, Rao SX, Shen JZ, Chen CZ, Zhang SJ, Shi WB. Ferucarbotran versus Gd-DTPA-enhanced MR imaging in the detection of focal hepatic lesions. World J Gastroenterol 2007; 13(36): 4891-4896 [PMID: 17828821 DOI: 10.3748/wjg.v13.i36.4891] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
46 Frericks BB, Loddenkemper C, Huppertz A, Valdeig S, Stroux A, Seja M, Wolf K, Albrecht T. Qualitative and Quantitative Evaluation of Hepatocellular Carcinoma and Cirrhotic Liver Enhancement Using Gd-EOB-DTPA. American Journal of Roentgenology 2009;193:1053-60. [DOI: 10.2214/ajr.08.1946] [Cited by in Crossref: 120] [Cited by in F6Publishing: 42] [Article Influence: 9.2] [Reference Citation Analysis]
47 Griffin N, Addley H, Sala E, Shaw AS, Grant LA, Eldaly H, Davies SE, Prevost T, Alexander GJ, Lomas DJ. Vascular invasion in hepatocellular carcinoma: is there a correlation with MRI? Br J Radiol 2012;85:736-44. [PMID: 21385912 DOI: 10.1259/bjr/94924398] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]